Advanced search
Publication Cover
OncoImmunology Volume 9, 2020 - Issue 1
Submit an article Journal homepage
2,518
Views
8
CrossRef citations to date
0
Altmetric
Back Matter

 RRx-001, a first-in-class small molecule inhibitor of MYC and a downregulator of CD47, is an "erythrophagoimmunotherapeutic"

Bryan Oronskya Clinical and Scientific Department, EpicentRx, Inc, La Jolla, CA, USACorrespondence[email protected]
,
Corey A. Cartera Clinical and Scientific Department, EpicentRx, Inc, La Jolla, CA, USA
,
Scott Caroena Clinical and Scientific Department, EpicentRx, Inc, La Jolla, CA, USA
,
Curtis Scribnera Clinical and Scientific Department, EpicentRx, Inc, La Jolla, CA, USA
,
Arnold Oronskyb Clinical and Scientific Department, InterWest Partners, Menlo Park, CA, USA
&
Tony R. Reida Clinical and Scientific Department, EpicentRx, Inc, La Jolla, CA, USA
Article: 1746172 | Received 04 Feb 2020, Accepted 11 Feb 2020, Published online: 03 Apr 2020

References

  • Oronsky B, Scicinski J, Cabrales P, Minchinton A. RRx-001, an epigenetic-based radio- and chemosensitizer, has vascular normalizing effects on SCCVII and U87 tumors. Clin Epigenetics. 2016 May 11;8:53. doi:10.1186/s13148-016-0220-7.
  • Raghunand N, Scicinski J, Guntle GP, Jagadish B, Mash EA, Bruckheimer E, Oronsky B, Korn RL. Magnetic resonance imaging of RRx-001 pharmacodynamics in preclinical tumors. Oncotarget. 2017 Jun 12;8(60):102511–2. doi:10.18632/oncotarget.18455.
  • Oronsky B, Scribner C, Aggarwal R, Cabrales P. RRx-001 protects normal tissues but not tumors via Nrf2 induction and Bcl-2 inhibition. J Cancer Res Clin Oncol. 2019 Aug;145(8):2045–2050. doi:10.1007/s00432-019-02958-4.
  • Zhao H, Ning S, Nolley R, Scicinski J, Oronsky B, Knox SJ, Peehl DM. The immunomodulatory anticancer agent, RRx-001, induces an interferon response through epigenetic induction of viral mimicry. Clin Epigenetics. 2017 Jan 19;9:4. doi:10.1186/s13148-017-0312-z.
  • Scicinski J, Oronsky B, Ning S, Knox S, Peehl D, Kim MM, Langecker P, Fanger G. NO to cancer: the complex and multifaceted role of nitric oxide and the epigenetic nitric oxide donor, RRx-001. Redox Biol. 2015 Dec;6:1–8. doi:10.1016/j.redox.2015.07.002.
  • Fens MH, Cabrales P, Scicinski J, Larkin SK, Suh JH, Kuypers FA, Oronsky N, Lybeck M, Oronsky A, Oronsky B. Targeting tumor hypoxia with the epigenetic anticancer agent, RRx-001: a superagonist of nitric oxide generation. Med Oncol. 2016 Aug;33(8):85. doi:10.1007/s12032-016-0798-9.
  • Scicinski J, Oronsky B, Taylor M, Luo G, Musick T, Marini J, Adams CM, Fitch WL. Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent. Drug Metab Dispos. 2012 Sep;40(9):1810–1816. doi:10.1124/dmd.112.046755.
  • Oronsky B, Paulmurugan R, Foygel K, Scicinski J, Knox SJ, Peehl D, Zhao H, Ning S, Cabrales P, Summers TA Jr, et al. RRx-001: a systemically non-toxic M2-to-M1 macrophage stimulating and prosensitizing agent in Phase II clinical trials. Expert Opin Investig Drugs. 2017 Jan;26(1):109–119. doi:10.1080/13543784.2017.1268600.
  • Oliveira C, Benfeito S, Fernandes C, Cagide F, Silva T, Borges F. NO and HNO donors, nitrones, and nitroxides: past, present, and future. Med Res Rev. 2018 Jul;38(4):1159–1187. doi:10.1002/med.21461.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.